News
BMRN
59.57
+3.86%
2.22
Bio-Techne Corp. Stock Rises 20.1%, Outperforms Peers
Dow Jones · 18h ago
Did New VOXZOGO and BMN 333 Data Just Shift BioMarin Pharmaceutical's (BMRN) Investment Narrative?
Simply Wall St · 3d ago
Incyte Corp. Stock Rises 5.5%, Outperforms Peers
Dow Jones · 3d ago
Spruce Biosciences names Agnieszka Jurecka vice president, medical affairs
PUBT · 4d ago
H.C. Wainwright Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN)
TipRanks · 4d ago
Weekly Report: what happened at BMRN last week (0615-0619)?
Weekly Report · 4d ago
3 US Pharmaceutical Stocks With Cash Flow And Pricing Risk
Simply Wall St · 6d ago
Bio-Techne Corp. Stock Rallies 5.3%, Outperforms Peers
Dow Jones · 06/18 20:35
BioMarin’s IMPALA Study Aims to Boost Palynziq Value With Better Tolerability
TipRanks · 06/17 16:32
BioMarin Pharmaceutical (BMRN) Stock Could Be 36.7% Undervalued After ENDO 2026 Data
Simply Wall St · 06/16 21:17
BioMarin’s Voxzogo and BMN 333 show impact in hypochondroplasia, achondroplasia
TipRanks · 06/16 13:17
BioMarin Pharmaceutical Presented New Data From Phase 2 Three-Year Extension Study Of VOXZOGO In 13 Children With Hypochondroplasia That Demonstrated Sustained Improvements In Annualized Growth Velocity And Height Standard Deviation Score
Benzinga · 06/16 13:13
BioMarin says VOXZOGO lifts height SDS 0.72 over three years in hypochondroplasia study at ENDO 2026
PUBT · 06/16 13:05
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
PR Newswire · 06/16 13:05
Incyte Corp. Stock Slips 6.0%, Underperforms Peers
Dow Jones · 06/15 20:34
Weekly Report: what happened at BMRN last week (0608-0612)?
Weekly Report · 06/15 10:38
2 Profitable Stocks Worth Your Attention and 1 We Find Risky
Barchart · 06/11 03:36
Is VOXZOGO’s Hypochondroplasia Data and Amicus Deal Reshaping the Investment Case for BioMarin (BMRN)?
Simply Wall St · 06/09 17:28
Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer
TipRanks · 06/09 11:42
Weekly Report: what happened at BMRN last week (0601-0605)?
Weekly Report · 06/08 10:33
More
Webull provides a variety of real-time BMRN stock news. You can receive the latest news about Biomarin Pharmaceutical Inc through multiple platforms. This information may help you make smarter investment decisions.
About BMRN
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its Galafold (migalastat) is the first oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease.